Home > Press > Nanophase Applies for Listing on NASDAQ Capital Market
Abstract:
Nanophase Technologies Corporation (Nasdaq:NANX), a technology leader in the development of advanced nanoengineered products, announced today that it has applied to transfer its listing from the NASDAQ Global Market to the NASDAQ Capital Market.
Nanophase president and CEO Jess Jankowski commented, "We initially chose to be listed on the NASDAQ Global Market in 1997, but based on our current market capitalization and the listing criteria for the NASDAQ Global Market, we are now a better fit for the Nasdaq Capital Market trading system. We believe that applying for listing on the NASDAQ Capital Market serves the best interests of Nanophase and its shareholders."
Jankowski continued, "There are approximately 500 companies listed on the Nasdaq Capital Market, the largest of which has a market capitalization exceeding $2 billion. As a small-cap growth company, we believe the Capital Market will provide an appropriate platform for the listing of our securities. Companies listed on the NASDAQ Capital Market enjoy the benefits of a NASDAQ listing with peers generally closer to Nanophase in size. We are looking forward to continuing our longstanding relationship with NASDAQ."
On May 17, 2011, the Company received a notice from The NASDAQ Stock Market stating that the Company's most recently reported Shareholder's Equity of $9,979,845 was below the $10,000,000 required by NASDAQ Listing Rule 5450(b)(1)(A) (the "Rule"), and therefore, the Company was no longer in compliance with the continuing listing standards for the NASDAQ Global Market. The NASDAQ notice stated that the Company has been provided 45 calendar days to submit a plan to regain compliance or to apply for an alternate market listing. If such a plan were accepted, the Company would then have up to 180 days to evidence compliance. The NASDAQ notice has no immediate effect on the listing of the Company's common stock, which continues to trade under the symbol "NANX." The Company believes that a successful transfer to the NASDAQ Capital Market would continue to provide its shareholders the advantages of a NASDAQ listing.
####
About Nanophase Technologies Corporation
Nanophase Technologies Corporation (NANX), www.nanophase.com, is a leader in nanomaterials technologies and provides nanoengineered solutions for multiple industrial product applications. Using a platform of patented and proprietary integrated nanomaterial technologies, the Company creates products with unique performance attributes from two ISO 9001:2008 and ISO 14001 facilities. Nanophase delivers commercial quantity and quality nanoparticles, coated nanoparticles, and nanoparticle dispersions in a variety of media.
For more information, please click here
Contacts:
Nancy Baldwin
Investor Relations
630-771-6708
Copyright © GlobeNewswire, Inc.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||